Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00728390 · ClinicalTrials.gov registry record · Phase 1
A Safety And Efficacy Study Of The Combination Of Oral PF-00299804 And Intravenous CP-751,871 Given Every 3 Weeks
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 74
- Enrollment target
NCT00728390 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 74 participants.
The verdict
NCT00728390, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 74 participants
- Enrollment target
Study Summary
This study will explore the combination of the oral drug PF-00299804 and intravenous CP-751,871 in patients with advanced solid tumor. Each of these drugs have been given separately to patients in prior studies, and this study is to establish the safety and efficacy of the combination.
Interventions
- DRUG PF-00299804
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 74 participants |
| Start Date | 2008-12-15 |
| Est. Completion | 2013-01-29 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00728390
The ClinicalTrials.gov registry entry for NCT00728390 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 74 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PF-00299804 is the first listed.
NCT00728390 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00728390 about?
NCT00728390 is a clinical study titled "A Safety And Efficacy Study Of The Combination Of Oral PF-00299804 And Intravenous CP-751,871 Given Every 3 Weeks". This study will explore the combination of the oral drug PF-00299804 and intravenous CP-751,871 in patients with advanced solid tumor. Each of these drugs have been given separately to patients in prior studies, and this study is to establish the safety and efficacy of the combination.
What is the current status of trial NCT00728390?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 74 participants. The study started on 2008-12-15. Estimated completion is 2013-01-29.
What interventions are being tested in trial NCT00728390?
The interventions under investigation include: PF-00299804 (DRUG).
Who is sponsoring clinical trial NCT00728390?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.